Global Molecular Diagnostics Cancer Oncology Market 2016-2019 - Greater Understanding of the Role of Genetic Material in Disease and Health

News provided by

Mar 01, 2016, 10:10 ET

DUBLIN, March 1, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/f5d98x/molecular) has announced the addition of the "Molecular Diagnostics Cancer Oncology - Global Market Size, Strategy and Forecasts - 2016 to 2019" report to their offering.

Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

A market that just keeps on growing. Molecular Diagnostics is positioned to directly benefit from the explosion in genomics knowledge. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

- personalized medicine
- pharmacogenomics
- pathogen evolution
- next generation sequencing
- emergence of new economies with large markets
- greater understanding of the role of genetic material in Disease and Health

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

The report data is designed to be used! The unit volumes of tests performed is presented. Use our pricing scenarios or use your own. Project your market share and your price to reliably generate revenue forecasts or understand your own current market share position. Detailed Market Forecasts provide Price, Volume and Revenue Forecasts individually broken out by year for Oncology Testing.

Key Topics Covered:

1. Introduction and Market Definition
1.1 What is Molecular Diagnostics
1.2 The Diagnostics Revolution
1.3 Market Definition
1.3.1 Volumes
1.3.2 Prices
1.3.3 Revenue Market Size
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. Market Overview
2.1 Market Participants
2.1.1 Supplier/pharmaceutical
2.1.2 Independent lab specialized/esoteric
2.1.3 Independent lab national/regional
2.1.4 Independent lab analytical
2.1.5 Public National/regional lab
2.1.6 Hospital lab
2.1.7 Physician lab
2.1.8 Audit body
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Lab's
2.3.4 Physician's and POCT
2.4 Profiles of Key MDx Companies
2.4.1 Roche Molecular Diagnostics
2.4.2 Illumina
2.4.3 Hologic
2.4.4 Agilent/Dako
2.4.5 Qiagen
2.4.6 Myriad Genetics
2.4.7 Becton, Dickinson & Co.
2.4.8 Abbott Laboratories
2.4.9 Cepheid
2.4.10 Genomic Health
2.4.11 Grifols
2.4.12 bioMérieux
2.4.13 Foundation Medicine
2.4.14 Agendia
2.4.15 Thermo Fisher
2.4.16 Signal Genetics LLC
2.4.17 Siemens Healthcare
2.5 Market Shares of Key MDx Players - Analysis

3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostic Definitions Create New Markets
3.1.2 Aging Population a Boon for Diagnostics.
3.1.3 Pharmacogenomics Drives Further Growth.
3.1.4 Point of Care Testing can increase demand
3.1.5 Liquid Biopsy
3.2 Factors Limiting Growth
3.2.1 Increased Competition Lowers Price
3.2.2 Lower Costs.
3.2.3 Testing usage analysis curtailing growth.
3.2.4 Wellness has a downside
3.2.5 Point of Care Testing
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role.
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing Fuels a Revolution
3.4.2 Impact of NGS on pricing
3.4.3 POCT/Self Testing Disruptive Force
3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.5 CGES Testing, A Brave New World
3.4.6 Biochips/Giant magneto resistance based assay

4. Molecular Diagnostics Recent Developments
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
4.3 CollabRx and GeneInsight to Collaborate on Service for Clinical
4.48 Transgenomic Closes Public Offering of Stock, Warrants
4.49 Qiagen Discloses $114.2M Price Tag for Enyzmatics Acquisition
4.51 GenomeDx Biosciences Implements Clarity LIMS
4.52 Merck Serono and Sysmex Inostics Announce Testing Center
4.53 Lifecode Receives CAP Accreditation, Discloses Funding
4.54 Baylor College of Medicin, Miraca Holdings finalize joint venture.
4.55 23andMe Gets FDA Clearance to Market Bloom Syndrome Carrier Test
4.57 Trinity Biotech Revenues Grow by 15%
4.58 Google's Latest Healthcare Initiative
4.60 Agena Bioscience Launches Smaller Format MassArray
4.61 QuantRx® Biomedical Provides Update on Technological Progress
4.62 The Journal of Molecular Diagnostics Publishes Special Article
4.63 Caprion Licenses Indi's Xpresys as Part of Larger Clinical Push
4.64 MDxHealth's ConfirmMDx Genes Detect Prostate Cancer
4.65 Atossa Genetics Announces That Its Subsidiary The National Reference Laboratory for Breast Health Has Received Accreditation
4.66 Nuclea Bio Plans Entry into Clinical Proteomics
4.67 Personal Genome Diagnostics Aims for FDA Clearance
4.68 Enzo Biochem Announces New Molecular Platform
4.69 Multiplicom, Premaitha Develop CE-IVDs
4.70 Regulating the Next Generation of Genetic Testing
4.71 BioReference Laboratories, Inc. Launches an Advanced Tumor Sequencing Program
4.72 Cytogenetics Become First Certified Lab to Offer Microarray Testing
4.73 Results Support Clinical Validity of Quantose IGT(TM) Diabetes Test
4.74 Accelerate Diagnostics' 2014 Revenues Rise Sharply
4.75 NanoString's Q4 Revenues Jump 54 Percent
4.76 New Aussie Firm Life Letters Launches Carrier, PGx Testing for Consumers
4.77 HTG Molecular Reports 50 Percent Increase in 2014 Revenues
4.80 Genomic Vision, Quest Extend Pact for Molecular Combing Technology
4.81 ACT Genomics Raises $8M in Private Funding Round
4.82 NGS-based Cancer MDx Firm Lifecode Raises $20.5M, Receives CAP Accreditation
4.83 Invitae Goes Public with $101.6M Offering
4.84 Quidel Q4 Revenues Grow 27 Percent on Infectious Disease Sales
4.85 Rosetta Signs Deal to Promote Precipio's Cancer Diagnostics
4.86 Premaitha Iona NIPT Lands CE Mark
4.87 Sera Increases Series B Round to $25M with $5M from Gates Foundation
4.88 T2 Biosystems Inks $8.5M Lyme Disease Dx Deal with Canon US Life Sciences
4.89 Invitae Amends IPO Filing Targeting up to $92.3M
4.90 Biofortuna Closes $2.2M Funding Round
4.91 Roche MDx Sales Help Drive 2014 Diagnostics Revenues up 3 Percent
4.92 AltheaDx Increases Target Amount on Proposed IPO to $74.3M
4.93 BioMerieux 2014 Revenues Increase 7 Percent
4.94 Cypher Genomics and Sequenom Announce Development Agreement
4.95 Abcam to Acquire Firefly BioWorks for $28M
4.97 Human Longevity, Genentech Ink Deal to Sequence Thousands of Genomes
4.98 GenMark Projects 52 Percent Growth in Q4 Revenues
4.99 Amarantus Acquires DioGenix for up to $10.9M
4.100 Roche to Invest up to $1.2B in Foundation Medicine, Take Majority Stake
4.101 DiaCarta Raises $8M in Series A Round
4.102 Epic Sciences' Cancer Dx Laboratory Receives CLIA Certification
4.103 Adaptive Biotechnologies Acquires Sequenta
4.104 Aegis Sciences Acquires MDx Firm Diagnovus
4.105 Interleukin Genetics Secures $10M in Financing
4.106 Premaitha NIPT Test Receives ISO Certification
4.107 HTG Molecular Diagnostics Files for IPO of up to $60M
4.108 CardioDx Raises $35M
4.109 MolecularMD Receives CAP Accreditation
4.110 14M Genomics Secures £12.5M Equity Financing for Oncology Dx
4.111 Protagen Closes First Part of Financing Round
4.112 Glyconics Inks Exclusive Licensing Deal
4.113 Great Basin Scientific Begins Trial for Staph Assay
4.114 Response Genetics Receives NYS Approval for Cancer Test
4.115 Claritas Genomics Adopts NextCode Health Platform to Interpret NGS Tests
4.116 FDA Clears Quidel's MDx for Bordetella Pertussis
4.117 FDA Clears Additional Flu Strains for Focus' MDx Assay
4.118 Novacyt Raises $3.8M in Private Equity
4.119 Good Start Genetics Licenses PGS Technology from Johns Hopkins
4.120 Metamark's Cambridge Lab Receives CAP Accreditation
4.121 Australia's VCGS Inks Deal with Illumina to Develop NIPT
4.123 Personalized Medicine Firm Newtopia Garners Investment from Bloom Burton
4.124 Roche to Acquire Ariosa Diagnostics
4.125 Biological Dynamics secures $26.8M Series C for further molecular diagnostics growth
4.126 NEO New Oncology begins study on molecular diagnostics for lung cancer patients
4.127 Qvella raises $20 million U.S. Series A round
4.128 Enzo Biochem Demonstrates Greater Sensitivity of Its AmpiProbe Platform for Molecular Diagnostics

5. Country Market Sizes - North America
5.1 United States of America
5.1.3 MDx Oncology Testing - Volumes, Prices, Revenues
5.2 Canada
5.2.3 MDx Oncology Testing - Volumes, Prices, Revenues

6. Country Markets - Europe
6.1 France
6.1.3 MDx Oncology Testing - Volumes, Prices, Revenues
6.2 Germany
6.2.3 MDx Oncology Testing - Volumes, Prices, Revenues
6.3 United Kingdom
6.3.3 MDx Oncology Testing - Volumes, Prices, Revenues
6.4 Spain
6.4.3 MDx Oncology Testing - Volumes, Prices, Revenues
6.5 Italy
6.5.3 MDx Oncology Testing - Volumes, Prices, Revenues
6.6 Switzerland
6.6.3 MDx Oncology Testing - Volumes, Prices, Revenues
6.7 Czech Republic
6.7.3 MDx Oncology Testing - Volumes, Prices, Revenues
6.8 Belgium
6.8.3 MDx Oncology Testing - Volumes, Prices, Revenues
6.9 Russia
6.9.3 MDx Oncology Testing - Volumes, Prices, Revenues
6.10 Remainder of Europe and Former Soviet Union
6.10.3 MDx Oncology Testing - Volumes, Prices, Revenues

7. Country Markets - Asia Pacific
7.1 China
7.1.3 MDx Oncology Testing - Volumes, Prices, Revenues
7.2 Japan
7.2.3 MDx Oncology Testing - Volumes, Prices, Revenues
7.3 South Korea
7.3.3 MDx Oncology Testing - Volumes, Prices, Revenues
7.4 India
7.4.3 MDx Oncology Testing - Volumes, Prices, Revenues
7.5 Australia
7.5.3 MDx Oncology Testing - Volumes, Prices, Revenues
7.6 Rest of Asia Pacific
7.6.3 MDx Oncology Testing - Volumes, Prices, Revenues

8. Country Markets - Latin America, Africa & The Middle East
8.1 Brazil
8.1.3 MDx Oncology Testing - Volumes, Prices, Revenues
8.2 Mexico
8.2.3 MDx Oncology Testing - Volumes, Prices, Revenues
8.3 Remainder of Latin America
8.3.3 MDx Oncology Testing - Volumes, Prices, Revenues
8.4 Africa & The Middle East
8.4.3 MDx Oncology Testing - Volumes, Prices, Revenues

9. Global Market Summary
9.1 Global Market
9.1.3 MDx Oncology Testing - Volumes, Prices, Revenues

Appendices
I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule - National Limit and Midpoint
II. FDA Approved Human Genetic Tests
III. FDA Approved Microbial Tests
III. FDA Approved Pharmacogenomics Tests

For more information visit http://www.researchandmarkets.com/research/f5d98x/molecular